This section highlights FDA-related milestones and regulatory updates for drugs developed by Silence Therapeutics (SLNCF).
Over the past two years, Silence Therapeutics has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as
divesiran and zerlasiran. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend.
Select a button below to view the list of FDA events for that drug.
Divesiran FDA Regulatory Events
Divesiran is a drug developed by Silence Therapeutics for the following indication: In patients with polycythemia vera.
This drug is under review by the U.S. Food and Drug Administration (FDA).
Below is a timeline of key regulatory milestones for this therapy.
- Drug:
- divesiran
- Announced Date:
- November 4, 2026
- Indication:
- In patients with polycythemia vera
Announcement
Silence Therapeutics plc announced that data from its SANRECO Phase 2 study of divesiran, a first-in-class siRNA silencing TMPRSS6, in polycythemia vera (PV) was accepted for oral presentation at the 68th American Society of Hematology (ASH) Annual Meeting being held December 12-15, 2026 in New Orleans, LA.
Read Announcement
Zerlasiran FDA Regulatory Events
Zerlasiran is a drug developed by Silence Therapeutics for the following indication: In atherosclerotic cardiovascular disease (ASCVD) patients with high lipoprotein(a) [Lp(a)] levels (≥125 nmol/L).
This drug is under review by the U.S. Food and Drug Administration (FDA).
Below is a timeline of key regulatory milestones for this therapy.
- Drug:
- zerlasiran
- Announced Date:
- November 18, 2024
- Indication:
- In atherosclerotic cardiovascular disease (ASCVD) patients with high lipoprotein(a) [Lp(a)] levels (≥125 nmol/L).
Announcement
Silence Therapeutics today presented end-of-treatment data from its Phase 2 ALPACAR-360 study of zerlasiran, a short interfering RNA (siRNA), in atherosclerotic cardiovascular disease (ASCVD) patients with high lipoprotein(a) [Lp(a)] levels (≥125 nmol/L).
AI Summary
Silence Therapeutics presented end-of-treatment data today from its Phase 2 ALPACAR-360 study of zerlasiran, a short interfering RNA (siRNA) aimed at patients with atherosclerotic cardiovascular disease (ASCVD) who have high lipoprotein(a) levels (≥125 nmol/L). The study is the first to report time-averaged Lp(a) reductions that measure the treatment’s impact over longer periods, including the time between doses.
The results showed that different dosing regimens of zerlasiran (300 mg every 16 weeks, 300 mg every 24 weeks, or 450 mg every 24 weeks) led to more than 80% mean placebo-adjusted reduction in Lp(a) levels over 36 weeks, with maximum reductions exceeding 90%. Notably, these reductions persisted until the final visit 60 weeks after the first dose, and the treatment was well tolerated. These promising results will help guide the dosing strategy for upcoming Phase 3 trials.
Read Announcement